Recruiting studies: High Risk Newly Diagnosed Multiple Myeloma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Thera
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06140966 ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106710 Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT06407947 Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
Phase 2/Phase 3 · 6 location(s) · University Hopsital Schleswig Holstein Campus Lübeck · NCT05665140 A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Parti
Phase 1/Phase 2 · 32 location(s) · Regeneron Pharmaceuticals · NCT05828511 Horizon Two: HR NDMM (MMRC-100)
Phase 2 · 7 location(s) · Multiple Myeloma Research Consortium · NCT07053436 A Dietary Study for People With Multiple Myeloma
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07226609 Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Phase 4 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06409702

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.